Literature DB >> 15731924

Establishment and characterization of the permanent human cell line C3842 derived from a secondary chondrosarcoma in Ollier's disease.

Thomas Kalinski1, Sabine Krueger, Antje-Friederike Pelz, Peter Wieacker, Roland Hartig, Martin Röpke, Regine Schneider-Stock, Frank Dombrowski, Albert Roessner.   

Abstract

The permanent human cell line C3842 was established from a secondary chondrosarcoma in a typical case of Ollier's disease. In the present study, we analyzed the morphological, cytogenetic and molecular biological characteristics of the cultured cells in comparison with the original tumor and investigated the invasion properties of the tumor model using functional imaging of proteolysis, matrigel assay and chick chorioallantoic membrane assay. C3842 cells exhibit the typical features of malignant cartilage tumor cells in vitro, including the expression of collagen types II, IX, XI and aggrecan. The proteolytic ability of C3842 cells is attributed to the expression of several proteases, such as cathepsin B, urokinase plasminogen activator and matrix-metalloproteinase-2, which enable the cells to degrade collagen type I and to permeate matrigel matrix. In accordance with the biological features in vivo, C3842 cells are not able to invade through the epithelium of the chick chorioallantoic membrane. In conclusion, the cell line C3842 provides the first model of a secondary chondrosarcoma in Ollier's disease in vitro, which is characterized by distinct features of such malignant cartilage tumors.

Entities:  

Mesh:

Year:  2005        PMID: 15731924     DOI: 10.1007/s00428-004-1194-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  35 in total

1.  Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE.

Authors:  B Budowle; R Chakraborty; A M Giusti; A J Eisenberg; R C Allen
Journal:  Am J Hum Genet       Date:  1991-01       Impact factor: 11.025

2.  Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas.

Authors:  M Söderström; H T Aro; M Ahonen; N Johansson; A Aho; T Ekfors; T Böhling; V M Kähäri; E Vuorio
Journal:  APMIS       Date:  2001-04       Impact factor: 3.205

3.  Prognostic relevance of cell biologic and biochemical features in conventional chondrosarcomas.

Authors:  Thomas Aigner; Susanna Müller; Daniel Neureiter; Duane M Illstrup; Thomas Kirchner; Johannes Björnsson
Journal:  Cancer       Date:  2002-04-15       Impact factor: 6.860

4.  Cytogenetic aberrations and their prognostic impact in chondrosarcoma.

Authors:  Nils Mandahl; Pelle Gustafson; Fredrik Mertens; Måns Akerman; Bo Baldetorp; David Gisselsson; Sakari Knuutila; Henrik C F Bauer; Olle Larsson
Journal:  Genes Chromosomes Cancer       Date:  2002-02       Impact factor: 5.006

5.  Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype.

Authors:  S Krueger; U Kellner; F Buehling; A Roessner
Journal:  Cancer Gene Ther       Date:  2001-07       Impact factor: 5.987

6.  Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2.

Authors:  E I Deryugina; G X Luo; R A Reisfeld; M A Bourdon; A Strongin
Journal:  Anticancer Res       Date:  1997 Sep-Oct       Impact factor: 2.480

7.  Immunohistological study on collagenous proteins of benign and malignant human cartilaginous tumours of bone.

Authors:  Y Ueda; Y Oda; H Tsuchiya; K Tomita; I Nakanishi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

8.  Deletion 1p in a low-grade chondrosarcoma in a patient with Ollier disease.

Authors:  Y Y Ozisik; A M Meloni; S S Spanier; C H Bush; K L Kingsley; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1998-09

9.  Evaluation of an in vitro invasion assay for use on solid tissue samples and cultured cells.

Authors:  W B Mackinnon; R Hancock; M Dyne; P Russell; C E Mountford
Journal:  Invasion Metastasis       Date:  1992

Review 10.  Proteases as prognostic markers in cancer.

Authors:  M J Duffy
Journal:  Clin Cancer Res       Date:  1996-04       Impact factor: 12.531

View more
  6 in total

Review 1.  [Inflammation as molecular target in chondrosarcoma].

Authors:  T Kalinski
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production.

Authors:  Silvia Calabuig-Fariñas; Rosario Gil Benso; Karoly Szuhai; Isidro Machado; José Antonio López-Guerrero; Danielle de Jong; Amando Peydró; Teresa San Miguel; Lara Navarro; Antonio Pellín; Antonio Llombart-Bosch
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

3.  [Angiogenesis in cartilage tumors].

Authors:  T Kalinski; A Roessner
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

4.  Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.

Authors:  Yvonne M Schrage; Liesbeth Hameetman; Karoly Szuhai; Anne-Marie Cleton-Jansen; Antonie H M Taminiau; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

5.  Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.

Authors:  Twinkal C Pansuriya; Ronald van Eijk; Pio d'Adamo; Maayke A J H van Ruler; Marieke L Kuijjer; Jan Oosting; Anne-Marie Cleton-Jansen; Jolieke G van Oosterwijk; Sofie L J Verbeke; Daniëlle Meijer; Tom van Wezel; Karolin H Nord; Luca Sangiorgi; Berkin Toker; Bernadette Liegl-Atzwanger; Mikel San-Julian; Raf Sciot; Nisha Limaye; Lars-Gunnar Kindblom; Soeren Daugaard; Catherine Godfraind; Laurence M Boon; Miikka Vikkula; Kyle C Kurek; Karoly Szuhai; Pim J French; Judith V M G Bovée
Journal:  Nat Genet       Date:  2011-11-06       Impact factor: 41.307

6.  Curcumin blocks interleukin-1 signaling in chondrosarcoma cells.

Authors:  Thomas Kalinski; Saadettin Sel; Heiko Hütten; Martin Röpke; Albert Roessner; Norbert Nass
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.